In Phase C, members will get ABBV-744 and oral navitoclax. In Section D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment till ailment progression or perhaps the members are not able to tolerate the study drugs. Celastrol was discovered for a Myb inhibitor that suppressed C/EBPβ activity and https://abbv-744-in-clinical-tria80234.ziblogs.com/32032995/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies